secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2022-05-19T23:59:59+00:00
Accession:  0001437749-22-013082
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica shareholders approve 2M share increase in 2019 omnibus incentive plan and new director compensation cap
--------------------------------------------------------------------------------

- Shareholders approved amendment to 2019 Omnibus Incentive Plan, increasing authorized shares by 2,000,000.
- The amended plan imposes a dollar limit on non-employee director compensation per calendar year.
- All six director nominees were elected; Richard Pilnik received 3.4M for, 1.3M withheld.
- Baker Tilly US, LLP appointed as independent registered public accounting firm for 2022.
- The plan became effective May 18, 2022 and expires on May 21, 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922013082/0001437749-22-013082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774922013082/dmtp20220518_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-013082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer